159 related articles for article (PubMed ID: 35510149)
1. Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention.
Chang SM; Yu YT; Luan B; Hou AJ; Wang Y
J Interv Cardiol; 2022; 2022():9322460. PubMed ID: 35510149
[TBL] [Abstract][Full Text] [Related]
2. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Somuncu MU; Akgun T; Cakır MO; Akgul F; Serbest NG; Karakurt H; Can M; Demir AR
J Atheroscler Thromb; 2019 Nov; 26(11):970-978. PubMed ID: 30996145
[TBL] [Abstract][Full Text] [Related]
3. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
Zhang Q; Hu M; Ma S
J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
[TBL] [Abstract][Full Text] [Related]
4. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction.
Søndergaard FT; Beske RP; Frydland M; Møller JE; Helgestad OKL; Jensen LO; Holmvang L; Goetze JP; Engstrøm T; Hassager C
Eur Heart J Acute Cardiovasc Care; 2023 Jan; 12(1):48-52. PubMed ID: 36355574
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
[TBL] [Abstract][Full Text] [Related]
6. The Value of Combining Plasma D-Dimer and Endothelin-1 Levels to Predict No-Reflow After Percutaneous Coronary Intervention of ST-Segment Elevation in Acute Myocardial Infarction Patients with a Type 2 Diabetes Mellitus History.
Gao R; Wang J; Zhang S; Yang G; Gao Z; Chen X
Med Sci Monit; 2018 May; 24():3549-3556. PubMed ID: 29806659
[TBL] [Abstract][Full Text] [Related]
7. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Aggarwal P; Rekwal L; Sinha SK; Nath RK; Khanra D; Singh AP
Ann Cardiol Angeiol (Paris); 2021 Jun; 70(3):136-142. PubMed ID: 33962782
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome and prognostic value of angiographic slow/no-reflow phenomenon after emergency percutaneous coronary intervention for ST-elevation myocardial infarction.
Bamarinejad A; Kermani-Alghoraishi M; Soleimani A; Roohafza H; Yazdekhasti S; MirmohammadSadeghi A; Bamarinejad F; Sadeghi M
Coron Artery Dis; 2024 Aug; 35(5):389-396. PubMed ID: 38563194
[TBL] [Abstract][Full Text] [Related]
9. Association between kaolin-induced maximum amplitude and slow-flow/no-reflow in ST elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
Li Q; Xie E; Tu Y; Wu Y; Guo Z; Li P; Li Y; Yu X; Ye Z; Yu C; Gao Y; Jingang Z
Int J Cardiol; 2022 Dec; 369():13-18. PubMed ID: 35970443
[TBL] [Abstract][Full Text] [Related]
10. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.
Süleymanoğlu M; Rencüzoğulları İ; Karabağ Y; Çağdaş M; Yesin M; Gümüşdağ A; Çap M; Gök M; Yıldız İ
Int J Cardiovasc Imaging; 2020 May; 36(5):789-796. PubMed ID: 31919706
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D level predicts angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with ST segment elevation myocardial infarction.
Şen Ö; Şen SB; Topuz AN; Topuz M
Biomark Med; 2021 Oct; 15(15):1357-1366. PubMed ID: 34533051
[No Abstract] [Full Text] [Related]
12. The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Quisi A; Alıcı G
J Clin Lab Anal; 2018 Nov; 32(9):e22598. PubMed ID: 29943408
[TBL] [Abstract][Full Text] [Related]
13. The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI.
Acet H; Ertaş F; Akil MA; Bilik MZ; Aydin M; Polat N; Yildiz A
Turk J Med Sci; 2016 Apr; 46(3):604-13. PubMed ID: 27513233
[TBL] [Abstract][Full Text] [Related]
14. The combination of neutrophil-to-lymphocyte ratio and platelet correlation parameters in predicting the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
Zhang Q; Hu M; Sun J; Ma S
Scand Cardiovasc J; 2020 Dec; 54(6):352-357. PubMed ID: 32597237
[TBL] [Abstract][Full Text] [Related]
15. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0.
Kai T; Oka S; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
Circ J; 2021 Sep; 85(10):1770-1778. PubMed ID: 34305099
[TBL] [Abstract][Full Text] [Related]
16. The impact of NT-proBNP on admission for early risk stratification of patients undergoing primary percutaneous coronary intervention.
Ayhan E; Isık T; Uyarel H; Ergelen M; Cicek G; Ozyurtlu F; Ghannadian B; Tanboga IH
Kardiol Pol; 2013; 71(2):165-75. PubMed ID: 23575711
[TBL] [Abstract][Full Text] [Related]
17. Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction.
Schram HCF; Hemradj VV; Hermanides RS; Kedhi E; Ottervanger JP;
Int J Cardiol; 2018 Aug; 265():12-17. PubMed ID: 29731349
[TBL] [Abstract][Full Text] [Related]
18. Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.
Qi Q; Niu J; Chen T; Yin H; Wang T; Jiang Z
Med Sci Monit; 2018 May; 24():2767-2776. PubMed ID: 29726480
[TBL] [Abstract][Full Text] [Related]
19. Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.
Topuz M; Oz F; Akkus O; Sen O; Topuz AN; Bulut A; Ozbicer S; Okar S; Koc M; Gur M
Perfusion; 2017 Apr; 32(3):206-213. PubMed ID: 27770057
[TBL] [Abstract][Full Text] [Related]
20. Platelet-Lymphocyte ratio is a predictor for the development of no-reflow phenomenon in patients with ST-segment elevation myocardial infarction after thrombus aspiration.
Şenöz O; Emren SV; Erseçgin A; Yapan Emren Z; Gül İ
J Clin Lab Anal; 2021 Jun; 35(6):e23795. PubMed ID: 33945171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
